← Back to Clinical Trials
Recruiting NCT00932139

NCT00932139 Effect of Electro-Acupuncture on Blood Pressure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00932139
Status Recruiting
Phase
Sponsor University of California, Irvine
Condition Hypertension
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2003-02
Primary Completion 2027-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Electro-acupuncture controlElectro-acupuncture test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2003-02 with a primary completion date of 2027-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Based on previous published research in animals and human, the investigators hypothesize that electroacupuncture (EA) will have a positive effect on hypertension.

Eligibility Criteria

Inclusion Criteria: * Patients with mild coronary disease, and no significant ECG change reflecting ischemia at rest. * Patients with high blood pressure with or without antihypertensive medication. Exclusion Criteria: * Pregnant or nursing women * Individuals with severe coronary disease (continuous angina) * Conduction abnormalities on ECG consistent with left bundle branch block * Cardiac arrhythmias associated with low blood pressure (90 mmHg) * Peripheral vascular disease * Orthopedic disease * Diabetic or psychological illness that could interfere with safe performance of exercise of psychophysiological stress testing * Those with known sensitivity to topical preparations or strong reactions to medical dressings and skin tapes

Contact & Investigator

Central Contact

Stephanie Tjen-A-Looi, PhD

✉ stjenalo@uci.edu

📞 9494005909

Principal Investigator

Shaista Malik, MD, PhD, MPH

PRINCIPAL INVESTIGATOR

University of California, Irvine

Frequently Asked Questions

Who can join the NCT00932139 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00932139 currently recruiting?

Yes, NCT00932139 is actively recruiting participants. Contact the research team at stjenalo@uci.edu for enrollment information.

Where is the NCT00932139 trial being conducted?

This trial is being conducted at Irvine, United States, Orange, United States.

Who is sponsoring the NCT00932139 clinical trial?

NCT00932139 is sponsored by University of California, Irvine. The principal investigator is Shaista Malik, MD, PhD, MPH at University of California, Irvine. The trial plans to enroll 160 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology